Navigation Links
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
Date:6/13/2013

RIDGEFIELD, Conn. and INDIANAPOLIS, June 13, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY) support the American Diabetes Association (ADA) call for an independent review of the safety data of incretin-based therapies. At BIPI and Lilly, patient safety is our top priority, and we support ongoing efforts to further understand whether diabetes or certain diabetes treatments may affect the risk of pancreatitis and pancreatic cancer.

We welcome future discussion with the ADA to determine how best we can support this initiative and to provide a valuable contribution.

BIPI and Lilly also welcome the discussions taking place this week at the National Institute of Diabetes and Digestive and Kidney Diseases–National Cancer Institute (NIDDK-NCI) Pancreatitis, Diabetes and Pancreatic Cancer Workshop. The workshop was convened, in part, to examine the latest data on whether there is a potential risk of pancreatitis and pancreatic cancer in people with type 2 diabetes as well as those treated with drugs classified as incretin-based therapies.

About Diabetes
Approximately 25.8 million Americans1 and an estimated 371 million people worldwide2 have type 1 or type 2 diabetes. Type 2 diabetes is the most common type, accounting for an estimated 90 to 95 percent of all diabetes cases.1 Diabetes is a chronic condition that occurs when the body does not properly either produce or use the hormone insulin.3 Diabetes was estimated to cost the U.S. $245 billion in 2012.4

Boehringer Ingelheim and Eli Lilly and Company
In January 2011, Boehringer Ingelheim and Eli Lilly and Company announced an alliance in the field of diabetes that centers on three compounds representing several of the largest diabetes treatment classes. This alliance leverages the companies' strengths as two of the world's leading pharmaceutical companies, combining Boehringer Ingelheim's solid track record of research-driven innovation and Lilly's innovative research, experience, and pioneering history in diabetes. By joining forces, the companies demonstrate commitment in the care of patients with diabetes and stand together to focus on patient needs. Find out more about the alliance at www.boehringer-ingelheim.com or www.lilly.com.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

Social responsibility is a central element of Boehringer Ingelheim's culture. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2012, Boehringer Ingelheim achieved net sales of about $19.1 billion (14.7 billion euro). R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.

For more information please visit www.us.boehringer-ingelheim.com.

About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, IN, Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we work to meet the diverse needs of people with diabetes through research and collaboration, a broad and growing product portfolio and a continued commitment to providing real solutions – from medicines to support programs and more – to make lives better.

For more information, visit www.lillydiabetes.com.

P-LLY

CONTACT:

Catherine London
Associate Director, Public Relations
Boehringer Ingelheim Pharmaceuticals, Inc.
Email: usnews@boehringer-ingelheim.com
Phone: (203) 798-4638

Tammy Hull
Communications Manager
Lilly Diabetes
Email: hullta@lilly.com
Phone: (317) 651-9116

References

  1. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and pre-diabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Center for Disease Control and Prevention, 2011.
  2. International Diabetes Federation. Diabetes Atlas, 5th Edition: Fact Sheet. 2012.
  3. International Diabetes Federation. IDF Diabetes Atlas, 5th Edition: What is Diabetes? http://www.idf.org/diabetesatlas/5e/what-is-diabetes. Accessed on: July 27, 2012.
  4. American Diabetes Association. Diabetes Care. 2013; 36(4):1033-1046.

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)
(Logo: http://photos.prnewswire.com/prnh/20110825/DE57898LOGO)


'/>"/>
SOURCE Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference
2. Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
3. ASCO 2013: Boehringer Ingelheim to Present Data Across Multiple Cancers, Including Different Treatment Settings for Advanced NSCLC
4. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
5. Boehringer Ingelheim to Announce Pivotal Phase 3 Hepatitis C Data at the International Liver Congress
6. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
7. Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment
8. Boehringer Ingelheim Announces Interim Results Evaluating Virologic Response Rates in HCV/HIV Co-Infected Patients Treated with Faldaprevir
9. Boehringer Ingelheim Cares Foundation Launches Online Giving Report
10. Boehringer Ingelheim Presents Efficacy Data for Tiotropium in Symptomatic Asthma Patients in Relation to Allergic Status
11. Pharmaceutical Leader Boehringer Ingelheim Selects Republica as Cross-Cultural Marketing Agency
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... , Feb. 20, 2017   Orion Health ... its Amadeus precision medicine platform to the ... currently manages over 110 million patient records globally. ... developing cloud-based, big data solutions built on modern, scalable ... Healthcare and Life Sciences. "The AWS Cloud gives healthcare ...
(Date:2/20/2017)... -- Research and Markets has announced the addition of ... Trends - Product (RFID refrigerators and RFID freezers), Application (Diagnostic centers, ... their offering. ... The Global RFID Blood Refrigerator and Freezer Market is poised to ... This industry report analyzes the global markets for ...
(Date:2/20/2017)... 2017   Alberty   Drugs , ... has announced a significant shift in focus ... programs to servicing local Veteran Affairs Centers (VA) and ... an increased need to secure cost effective treatments for ... locally for their goods & services. "The ...
Breaking Medicine Technology:
(Date:2/20/2017)... Fla. (PRWEB) , ... February 20, 2017 , ... Johns ... research and education building. A topping out ceremony on Friday marked the halfway point ... building, set to open in Fall 2018, will serve as a center for innovation ...
(Date:2/19/2017)... ... February 19, 2017 , ... Braun Industries will be ... & Exposition, the event will take place February 23-25, 2017 at the Calvin L. ... in Booth #909 with three new ambulances on display. , “JEMS ...
(Date:2/18/2017)... ... February 17, 2017 , ... Focused start-ups, not ... the industry, according to the recent NEJM Catalyst Insights Report on the New ... NEJM Catalyst Insights Council, a qualified group of U.S. executives, clinical leaders, and ...
(Date:2/18/2017)... , ... February 18, 2017 , ... ... provides the latest information and contact points to easily connect elderly veterans of ... assisted living, and elder-care funding. It also conveys material on this year's increase ...
(Date:2/17/2017)... TN (PRWEB) , ... February 17, 2017 , ... ... Inc. (ISTS) brings its educational assistance management solution to the exhibit floor for ... Center in Orlando, Fla. , From Feb. 19–23, 2017, more than 40,000 ...
Breaking Medicine News(10 mins):